Sarah Sammons: Fatty liver disease in breast cancer survivors

Sarah Sammons shared a post by NEJM on X/Twitter:

“We see a decent amount of fatty liver disease in breast cancer survivors and tamoxifen increases this risk. Not to mention normal BMI has benefits in BC survivors. I am seeing more and more survivors on GLP-1 agonists. It would be great to formally study the impacts.”

Quoting NEJM’s post:

“In a phase 2 trial in patients with metabolic dysfunction–associated steatohepatitis and moderate or severe fibrosis, tirzepatide was more effective than placebo with respect to resolution of MASH without worsening of fibrosis.”

Visit the article website.
Source: Sarah Sammons/X and NEJM/X

Sarah Sammons is a medical oncologist at Dana-Farber’s Breast Oncology Center specializing in treating patients with all stages of breast cancer. She is particularly focusing on improving outcomes for those with metastatic breast cancer.

Through leading numerous clinical trials, she has developed new treatment options for breast cancer patients. Additionally, Dr. Sammons is skilled in treating brain metastases.